Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study

Anna But, Marie L. De Bruin, Marloes T. Bazelier, Vidar Hjellvik, Morten Andersen, Anssi Auvinen, Jakob Starup-Linde, Marjanka K. Schmidt, Kari Furu, Frank de Vries, Oystein Karlstad, Nils Ekstrom, Jari Haukka

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1691-1703
Number of pages13
JournalDiabetologia
Volume60
Issue number9
DOIs
Publication statusPublished - Sep 2017

Keywords

  • Cancer risk
  • Cohort study
  • Common datamodel
  • Cumulative treatment time
  • Detemir
  • Glargine
  • Human insulin
  • Insulinanalogues
  • Newinsulinuser
  • Poissonmodel
  • Rate ratio
  • Semi-aggregate
  • Site-specific
  • DIABETES-MELLITUS
  • COLORECTAL-CANCER
  • GLYCEMIC CONTROL
  • GLARGINE USE
  • NPH INSULIN
  • METAANALYSIS
  • ASSOCIATION
  • BIAS
  • MALIGNANCIES
  • MORTALITY

Cite this

But, A., De Bruin, M. L., Bazelier, M. T., Hjellvik, V., Andersen, M., Auvinen, A., Starup-Linde, J., Schmidt, M. K., Furu, K., de Vries, F., Karlstad, O., Ekstrom, N., & Haukka, J. (2017). Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. Diabetologia, 60(9), 1691-1703. https://doi.org/10.1007/s00125-017-4312-5